drugset / Trial / NCT00603356
Phase I Study of OSI-930 and Erlotinib in Cancer Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a Phase I, dose escalation, safety study of OSI-930 and Erlotinib in cancer tumors.
Timeline
- Start
- 2007-11
- Primary completion
- 2010-04
- Completion
- 2010-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erlotinib | Small molecule | — | Oral |
| Subject | OSI-930 | Small molecule | — | Oral |